154 related articles for article (PubMed ID: 19210289)
1. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.
Vlachogiannakos J; Saveriadis AS; Viazis N; Theodoropoulos I; Foudoulis K; Manolakopoulos S; Raptis S; Karamanolis DG
Aliment Pharmacol Ther; 2009 May; 29(9):992-9. PubMed ID: 19210289
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites.
Kalambokis GN; Mouzaki A; Rodi M; Pappas K; Fotopoulos A; Xourgia X; Tsianos EV
Clin Gastroenterol Hepatol; 2012 Jul; 10(7):815-8. PubMed ID: 22391344
[TBL] [Abstract][Full Text] [Related]
3. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
[TBL] [Abstract][Full Text] [Related]
5. Splanchnic endotoxin levels in cirrhotic rats induced by carbon tetrachloride.
Chu CJ; Lee FY; Wang SS; Chang FY; Lin HC; Lu RH; Chan CC; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):196-204. PubMed ID: 10746415
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.
Kalambokis GN; Mouzaki A; Rodi M; Tsianos EV
Liver Int; 2012 Mar; 32(3):467-75. PubMed ID: 22098272
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
9. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
12. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis.
Pozzi M; Grassi G; Ratti L; Favini G; Dell'Oro R; Redaelli E; Calchera I; Boari G; Mancia G
Am J Gastroenterol; 2005 May; 100(5):1110-6. PubMed ID: 15842586
[TBL] [Abstract][Full Text] [Related]
13. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis.
Boleslawski E; Petrovai G; Truant S; Dharancy S; Duhamel A; Salleron J; Deltenre P; Lebuffe G; Mathurin P; Pruvot FR
Br J Surg; 2012 Jun; 99(6):855-63. PubMed ID: 22508371
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
15. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites.
Rincón D; Vaquero J; Hernando A; Galindo E; Ripoll C; Puerto M; Salcedo M; Francés R; Matilla A; Catalina MV; Clemente G; Such J; Bañares R
Liver Int; 2014 Nov; 34(10):1504-12. PubMed ID: 24661740
[TBL] [Abstract][Full Text] [Related]
16. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
Turco L; Garcia-Tsao G; Magnani I; Bianchini M; Costetti M; Caporali C; Colopi S; Simonini E; De Maria N; Banchelli F; Rossi R; Villa E; Schepis F
J Hepatol; 2018 May; 68(5):949-958. PubMed ID: 29331339
[TBL] [Abstract][Full Text] [Related]
17. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites.
Okumura H; Aramaki T; Katsuta Y; Satomura K; Akaike M; Sekiyama T; Terada H; Ohsuga M; Komeichi H; Tsutsui H
Am J Gastroenterol; 1991 Jan; 86(1):46-52. PubMed ID: 1986554
[TBL] [Abstract][Full Text] [Related]
18. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis.
Møller S; Hobolth L; Winkler C; Bendtsen F; Christensen E
Gut; 2011 Sep; 60(9):1254-9. PubMed ID: 21504996
[TBL] [Abstract][Full Text] [Related]
19. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
20. Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension.
Vlavianos P; Mac Mathuna P; Williams R; Westaby D
Clin Sci (Lond); 1999 May; 96(5):475-81. PubMed ID: 10209079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
